CA2303229A1 - Pentopyranosylnucleoside, its preparation and use - Google Patents

Pentopyranosylnucleoside, its preparation and use Download PDF

Info

Publication number
CA2303229A1
CA2303229A1 CA002303229A CA2303229A CA2303229A1 CA 2303229 A1 CA2303229 A1 CA 2303229A1 CA 002303229 A CA002303229 A CA 002303229A CA 2303229 A CA2303229 A CA 2303229A CA 2303229 A1 CA2303229 A1 CA 2303229A1
Authority
CA
Canada
Prior art keywords
equal
dmt
conjugate according
isobutyroyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002303229A
Other languages
French (fr)
Other versions
CA2303229C (en
Inventor
Christian Miculka
Norbert Windhab
Tilmann Brandstetter
Gerhard Burdinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303229A1 publication Critical patent/CA2303229A1/en
Application granted granted Critical
Publication of CA2303229C publication Critical patent/CA2303229C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/724—Devices having flexible or movable element
    • Y10S977/727—Devices having flexible or movable element formed from biological material
    • Y10S977/728—Nucleic acids, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/80—Nucleic acid, e.g. DNA or RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/832—Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/835—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial
    • Y10S977/836—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial having biological reactive capability
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/894—Manufacture, treatment, or detection of nanostructure having step or means utilizing biological growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/914—Protein engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/925—Bioelectrical

Abstract

The invention relates to a pentopyranosyl nucleoside of formula (I) or formula(II), to the production of said pentopyranosyl nucleoside, and to its use for producing a therapeutic agent, a diagnostic agent and/or an electronic component.

Claims (14)

1. Conjugate comprising a pentapyranosylnucleoside [sic] or a pentapyranosylnucleic [sic] acid and a biomolecule.
2. Conjugate according to Claim 1, comprising a pentopyranosylnucleoside of the formula (I), in which R1 is equal to H, OH, Hal where Hal is equal to Br or Cl or a radical selected from or -O-P[N(i-Pr)2]-(OCH2CH2CN) where i-Pr is equal to isopropyl, or OS c3 where S c3 is equal to a protective group, preferably a protective group which can be removed by base or metal catalysis, in particular an acyl group, particularly preferably a benzoyl group, R2, R3 and R4 independently of one another, identically or differently, are in each case H, Hal where Hal is equal to Br or Cl, NR5R6, OR7, SR8, =O, C n H2n+1 where n is an integer from 1-12, preferably 1-8, in particular 1-4, a .beta.-eliminable group, preferably a group of the formula -OCH2CH2R18 where R18 is equal to a cyano or p-nitrophenyl radical or a fluorenylmethyloxycarbonyl (Fmoc) radical, or (C n H2n)NR10R11 where R10R11 is equal to H, C n H2n+1 or R10R11 linked via a radical of the formula in which R12, R13, R14 and R15 independently of one another, identically or differently, are in each case H, OR7, where R7 has the abovementioned meaning, or C n H2n+1, or C n H2n-1, where n has the abovementioned meaning, and R5, R6, R7 and R8 independently of one another, identically or differently, is in each case H, C n H2n+1, or C n H2n-1, where n has the abovementioned meaning, -C(O)R9 where R9 is equal to a linear or branched, optionally substituted alkyl or aryl radical, preferably a phenyl radical, X, Y and Z independently of one another, identically or differently, is in each case =N-, =C(R16)- or -N(R17)-where R16 and R17 independently of one another, identically or differently, is in each case H or C n H2n+1 or (C n H2n)NR10R11 having the abovementioned meanings, and S c1 and S c2 independently of one another, identically or differently, is in each case H or a protective group selected from an acyl, trityl or allyloxycarbonyl group, preferably a benzoyl or 4,4'-dimethoxytrityl (DMT) group, or of the formula (II) in which R1' is equal to H, OH, Hal where Hal is equal to Br or Cl, or a radical selected from or -O-P[N(i-Pr)2]-(OCH2CH2CN) where i-Pr is equal to isopropyl, or OS c3 where S c3 is equal to a protective group, preferably a protective group which can be removed by base or metal catalysis, in particular an acyl group, particularly preferably a benzoyl group, R2', R3' and R4' independently of one another, identically or differently, are in each case H, Hal where Hal is equal to Br or Cl, =O, C n H2n+1 or -C n H2n-1, a .beta.-eliminable group, preferably a group of the formula -OCH2CH2R18 where R18 is equal to a cyano or p-nitrophenyl radical or a fluorenylmethyloxycarbonyl (Fmoc) radical, or (C n H2n)NR10'R11', where R10', R11', independently of one another has the abovementioned meaning of R10 or R11, and X' is =N-, =C(R16')- or -N(R17')-, where R16' and R17' independently of one another have the abovementioned meaning of R16 or R17, and S c1' and S c2' have the abovementioned meaning of S c1 and S c2.
3. Conjugate according to Claim 1 or 2, comprising at least one pentopyranosylnucleoside and, preferably, at least one allyloxy linker.
4. Conjugate according to one of Claims 1-3, characterized in that the pentopyranosylnucleoside is a ribo-, arabino-, lyxo- and/or xylopyranosylnucleoside, preferably a ribopyransoylnucleoside.
5. Conjugate according to one of Claims 1-4, characterized in that the pentopyranosyl moiety of the pentopyranosylnucleoside is in the D or L
configuration.
6. Conjugate according to one of Claims 1-5, characterized in that the pentopyranosylnucleoside employed is a pentopyranosyl purine, -2,6-di-aminopurine, -5-purinethiol, -pyridine, -pyrimidine, -adenosine, -guanosine, -isoguanosine, -6-thioguanosine, -xanthine, -hypoxanthine, -thymidine, -cytosine, -isocytosine, -indole, -tryptamine, -N-phthaloyl-tryptamine, -uracil, -caffeine, -theobromine, -theophylline, -benzotriazole or -acridine.
7. Conjugate according to one of Claims 2-6, characterized in that R2, R3, R4, R2', R3' and/or R4' is a 2-phthalimidoethyl or allyloxy radical or a radical of the formula -N[C(O)R9]2.
8. Conjugate according to one of claims 1-7, characterized in that the pentopyranosylnucloside is a [2',4'-di-O-benzoyl-.beta.-ribopyranosyl]nucleoside, in particular a [2',4'-di-O-benzoyl)-.beta.-ribopyranosyl]adenine, -guanine, -cytosine, -thymidine, -uracil, -xanthine or hypoxanthine, ~~an ~ N-benzoyl-2',4'-di-O-benzoylribopyranosylnucleoside, in particular an -adenine, -guanine or -cytosine, an N-isobutyroyl-2',4'-di-O-benzoylribopyranosylnucleoside, in particular an -adenine, -guanine or -cytosine, an O6-(2-cyanoethyl)-N2-isobutyroyl-2',4'-di-O-benzoylribo-pyranosylnucleoside, in particular a -guanine, an O6 (2-(4'-nitrophenyl)ethyl)-N2-isobutyroyl-2',4'-di-O-benzoylribopyranosylnucleoside, in particular a -guanine, a .beta.-ribopyranosylnucleoside, in particular a .beta.-ribopyranosyladenine, -guanine, -cytosine, -thymidine or -uracil, -xanthine or hypoxanthine, an N-benzoyl-, N-isobutyroyl-, O6-(2-cyanoethyl)- or O6-(2-(4-nitro-phenyl)ethyl)-N2-isobutyroyl-.beta.-ribopyranosylnucleoside, a 4'-DMT-pentopyranosylnucleoside, preferably a 4'-DMT-ribopyranosylnucleoside, in particular a 4'-DMT-ribopyranosyladenine, -guanine, -cytosine, -thymidine, -uracil, -xanthine or hypoxanthine, an N-benzoyl-4'-DMT-ribopyranosylnucleoside, in particular an N-benzoyl-4'-DMT-ribopyranosyladenine, -guanine or -cytosine, an N-isobutyroyl-4'-DMT-ribopyranosyl-nucleoside, in particular an N-isobutyroyl-4'-DMT-ribopyranosyladenine, -guanine,- or -cytosine, an O6-(2-cyanoethyl)-N2-isobutyroyl-4'-DMT-ribopyranosyl-nucleoside, in particular an O6-(2-cyanoethyl)-N2-isobutyroyl-4'-DMT-ribopyranosylguanine, an O6-(2-(-4-nitrophenyl)ethyl)-N2-isobutyroyl-4'-DMT-ribopyranosylnucleoside, in particular an O6-(2-(-4-nitrophenyl)ethyl)-N2-isobutyroyl-4'-DMT-ribopyranosylguanine or a .beta.-ribopyranosyl-N,N'-dibenzoyladenosine or a .beta.-ribopyranosyl-N,N'-dibenzoyl-guanosine.
9. Conjugate according to one of Claims 1-8, characterized in that the biomolecule is a peptide, protein or a nucleic acid.
10. Conjugate according to Claim 9, characterized in that the biomolecule is an antibody or a functional moiety thereof or a DNA and/or RNA occurring in its natural form.
11. Process for the preparation of a conjugate according to one of Claims 1-10, characterized in that a pentopyranosylnucleoside or a pentopyranosylnucleic acid is combined with a biomolecule.
12. Use of a conjugate according to one of Claims 1-10 for the production of a medicament, diagnostic and/or electronic component.
13. Use of a conjugate according to one of Claims 1-10 for the production of an array.
14. Diagnostic comprising a conjugate according to one of Claims 1-10.
CA002303229A 1997-09-22 1998-09-21 Pentopyranosylnucleoside, its preparation and use Expired - Fee Related CA2303229C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19741715A DE19741715A1 (en) 1997-09-22 1997-09-22 New pentopyranosyl nucleoside compounds
DE19741715.9 1997-09-22
PCT/EP1998/005997 WO1999015539A2 (en) 1997-09-22 1998-09-21 Pentopyranosyl nucleoside, and production and use of the same

Publications (2)

Publication Number Publication Date
CA2303229A1 true CA2303229A1 (en) 1999-04-01
CA2303229C CA2303229C (en) 2009-12-01

Family

ID=7843183

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002302414A Abandoned CA2302414A1 (en) 1997-09-22 1998-09-21 Process for the preparation of a pentopyranosylnucleoside
CA002303229A Expired - Fee Related CA2303229C (en) 1997-09-22 1998-09-21 Pentopyranosylnucleoside, its preparation and use
CA002303784A Abandoned CA2303784A1 (en) 1997-09-22 1998-09-21 Use of a pentopyranosylnucleoside for the production of an electronic component, and conjugates thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002302414A Abandoned CA2302414A1 (en) 1997-09-22 1998-09-21 Process for the preparation of a pentopyranosylnucleoside

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002303784A Abandoned CA2303784A1 (en) 1997-09-22 1998-09-21 Use of a pentopyranosylnucleoside for the production of an electronic component, and conjugates thereof

Country Status (10)

Country Link
US (8) US6506896B1 (en)
EP (3) EP1019423B1 (en)
JP (3) JP4674964B2 (en)
KR (3) KR20010024202A (en)
AT (3) ATE265462T1 (en)
AU (3) AU757983B2 (en)
BR (3) BR9812501A (en)
CA (3) CA2302414A1 (en)
DE (4) DE19741715A1 (en)
WO (3) WO1999015539A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2218726A1 (en) * 2001-07-19 2010-08-18 Nanogen Recognomics GmbH Sorting and immobilization system for nucleic acids using synthetic binding systems

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741715A1 (en) * 1997-09-22 1999-03-25 Hoechst Ag New pentopyranosyl nucleoside compounds
DE19741738A1 (en) * 1997-09-22 1999-03-25 Hoechst Ag Linker nucleoside(s) containing alkenyloxy or phthalimido-alkyl groups
DE19741739B4 (en) * 1997-09-22 2006-04-27 Nanogen Recognomics Gmbh Supramolecular mating system, its production and use
DE19815901A1 (en) 1998-04-08 1999-10-14 Aventis Res & Tech Gmbh & Co Process for the preparation of pentopyranosyl nucleosides
DE19837387A1 (en) 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co New nucleic acid analogs useful in therapeutic or diagnostic agents or electronic components, consist of 3'-deoxypentopyranosyl nucleosides
US20010049111A1 (en) * 1999-08-13 2001-12-06 Norbert Windhab Methods, procedures, and formats for using microelectronic array devices to perform multiplex immunoassay analyses
DE10010118A1 (en) * 2000-03-03 2001-09-20 Henkel Kgaa Coating system, useful for the production of microelectronics, comprises a pyranosyl nucleic acid comprises a pyranosephosphate back bone bonded to purine or pyrimidine bases.
DE10111681A1 (en) * 2001-03-09 2002-10-02 Nanogen Recognomics Gmbh Improved process for the production of pentopyranosyl nucleosides
AU2003219576A1 (en) * 2003-04-03 2004-10-25 Korea Advanced Institute Of Science And Technology Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
CA2463719A1 (en) * 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
JP5126706B2 (en) * 2007-02-16 2013-01-23 独立行政法人農業・食品産業技術総合研究機構 Method for synthesizing a library of compounds having two or more hydroxyl groups
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
WO2011005761A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc Novel nucleic acid prodrugs and methods use thereof
US10127349B2 (en) * 2010-07-16 2018-11-13 Elitechgroup B.V. Method of producing oligomer affinity pairs
WO2012039448A1 (en) 2010-09-24 2012-03-29 株式会社キラルジェン Asymmetric auxiliary group
RU2014105311A (en) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. METHODS FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
CN104684893B (en) 2012-07-13 2016-10-26 日本波涛生命科学公司 Asymmetric auxiliary group
RU2015104762A (en) 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. CHIRAL CONTROL
MX356830B (en) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Chiral nucleic acid adjuvant.
US9169256B2 (en) 2013-03-13 2015-10-27 Elitechgroup B.V. Artificial nucleic acids
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
ES2917473T3 (en) 2014-01-16 2022-07-08 Wave Life Sciences Ltd chiral design
US10870845B2 (en) 2014-07-01 2020-12-22 Global Life Sciences Solutions Operations UK Ltd Methods for capturing nucleic acids
US9593368B2 (en) 2014-07-01 2017-03-14 General Electric Company Methods for amplifying nucleic acids on substrates
US10472620B2 (en) 2014-07-01 2019-11-12 General Electric Company Method, substrate and device for separating nucleic acids
CN107556355B (en) * 2016-06-30 2021-10-22 上海兆维科技发展有限公司 Nucleoside diphosphite amide and preparation method thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2644817A (en) * 1949-10-28 1953-07-07 Merck & Co Inc 1-glycosido-5, 6 dimethyl benzimidazoles and process therefor
GB690119A (en) * 1950-07-13 1953-04-15 British Drug Houses Ltd Improvements in or relating to the manufacture of heterocyclic compounds
US2719843A (en) * 1951-10-24 1955-10-04 Davoll John Method of synthesizing nucleosides and analogous compounds and compounds prepared thereby
GB866815A (en) * 1957-06-14 1961-05-03 Pfizer & Co C Piperazine salts
US2993039A (en) * 1959-11-06 1961-07-18 Upjohn Co Preparing nu-glycosides of aldose and ketose sugars
US3658788A (en) * 1969-06-06 1972-04-25 Salk Inst For Biological Studi Aminooxazolines and products thereof and processes for synthesizing same
US3752804A (en) 1969-06-14 1973-08-14 Takeda Chemical Industries Ltd 2-allyloxyinosine-5'-phosphate and physiologically acceptable salts thereof
JPS5036087A (en) 1973-07-13 1975-04-04
JPS5821005B2 (en) * 1974-08-26 1983-04-26 株式会社クボタ Graphite nodularizing agent in spheroidal graphite cast iron production
US3995190A (en) 1974-09-19 1976-11-30 Butler, Binion, Rice, Cook & Knapp Mobile ion film memory
US4283773A (en) 1977-08-30 1981-08-11 Xerox Corporation Programmable master controller communicating with plural controllers
US4225410A (en) 1978-12-04 1980-09-30 Technicon Instruments Corporation Integrated array of electrochemical sensors
JPS55153796A (en) * 1979-05-21 1980-11-29 Meiji Seika Kaisha Ltd 5-fluorouracil nucleoside and its preparation
US4352795A (en) 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
JPS57146796A (en) * 1981-03-09 1982-09-10 Haruo Ogura Glycoside derivative
FI63596C (en) 1981-10-16 1983-07-11 Orion Yhtymae Oy MICROBIA DIAGNOSIS FOERFARANDE SOM GRUNDAR SIG PAO SKIKTSHYBRIDISERING AV NUCLEINSYROR OCH VID FOERFARANDET ANVAENDA KOMBINATIONER AV REAGENSER
US4476301A (en) * 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
CA1223831A (en) * 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US4580895A (en) 1983-10-28 1986-04-08 Dynatech Laboratories, Incorporated Sample-scanning photometer
CA1242486A (en) 1983-11-25 1988-09-27 John J. Comfort Automatic test equipment
US4661451A (en) 1984-02-06 1987-04-28 Ortho Diagnostic Systems, Inc. Methods for immobilizing and translocating biological cells
FI71768C (en) 1984-02-17 1987-02-09 Orion Yhtymae Oy Enhanced nucleic acid reagents and process for their preparation.
DE3434039A1 (en) 1984-09-17 1986-03-27 Behringwerke Ag, 3550 Marburg GLYCOPEPTIDES, METHOD FOR THEIR PRODUCTION AND THEIR USE
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4584075A (en) 1984-11-26 1986-04-22 Ionics Incorporated Process and apparatus for electrically desorbing components selectively sorbed on an electrolytically conducting barrier
GB8432118D0 (en) 1984-12-19 1985-01-30 Malcolm A D B Sandwich hybridisation technique
US4594135A (en) 1985-02-20 1986-06-10 Ionics Incorporated Process and apparatus for electrically desorbing components selectively sorbed on granules
US5096807A (en) 1985-03-06 1992-03-17 Murex Corporation Imaging immunoassay detection system with background compensation and its use
JPH0337770Y2 (en) 1985-03-30 1991-08-09
DE3513168A1 (en) 1985-04-12 1986-10-16 Thomas 8000 München Dandekar BIOSENSOR CONSISTING OF A SEMICONDUCTOR BASED ON SILICON OR CARBON-BASED (ELECTRONIC PART) AND NUCLEIN BASE (OR. OTHER BIOL. MONOMERS)
US4751177A (en) 1985-06-13 1988-06-14 Amgen Methods and kits for performing nucleic acid hybridization assays
US4816418A (en) 1985-07-22 1989-03-28 Sequoia-Turner Corporation Method and apparatus for performing automated, multi-sequential immunoassays
EP0213825A3 (en) 1985-08-22 1989-04-26 Molecular Devices Corporation Multiple chemically modulated capacitance
US4822566A (en) 1985-11-19 1989-04-18 The Johns Hopkins University Optimized capacitive sensor for chemical analysis and measurement
EP0228075B1 (en) 1986-01-03 1991-04-03 Molecular Diagnostics, Inc. Eucaryotic genomic dna dot-blot hybridization method
US5242797A (en) 1986-03-21 1993-09-07 Myron J. Block Nucleic acid assay method
US5125748A (en) 1986-03-26 1992-06-30 Beckman Instruments, Inc. Optical detection module for use in an automated laboratory work station
FR2604438B1 (en) * 1986-09-26 1988-12-23 Centre Nat Rech Scient NOVEL COUPLING CONJUGATES BETWEEN RNA OR DNA SEQUENCES AND A PROTEIN, THEIR PREPARATION PROCESS AND THEIR BIOLOGICAL APPLICATION
US4918056A (en) * 1986-10-14 1990-04-17 Health Research, Inc. (Roswell Park Division) 2-substituted arabinopyranosyl nucleosides and nucleotides
DE3750503T2 (en) 1986-10-22 1995-02-09 Abbott Lab Chemiluminescent acridinium and phenantridinium salts.
US4859538A (en) * 1986-11-20 1989-08-22 Ribi Hans O Novel lipid-protein compositions and articles and methods for their preparation
US4885211A (en) * 1987-02-11 1989-12-05 Eastman Kodak Company Electroluminescent device with improved cathode
YU57087A (en) 1987-04-01 1990-08-31 Centar Za Genticko Inzenjerstv Process for obtaining genome by hebridization and oligonucleotidic tests
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5114674A (en) 1987-05-01 1992-05-19 Biotronic Systems Corporation Added array of molecular chains for interfering with electrical fields
US4787963A (en) 1987-05-04 1988-11-29 Syntro Corporation Method and means for annealing complementary nucleic acid molecules at an accelerated rate
US5074977A (en) 1987-05-05 1991-12-24 The Washington Technology Center Digital biosensors and method of using same
EP0382736B1 (en) 1987-07-27 1994-11-02 Commonwealth Scientific And Industrial Research Organisation Receptor membranes
JP2603480B2 (en) * 1987-08-05 1997-04-23 住友製薬株式会社 Stabilized anthracyclines
PT88550A (en) 1987-09-21 1989-07-31 Ml Tecnology Ventures Lp PROCESS FOR THE PREPARATION OF NON-NUCLEOTIDIC LIGACATION REAGENTS FOR NUCLEOTIDIAL PROBES
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US4908112A (en) 1988-06-16 1990-03-13 E. I. Du Pont De Nemours & Co. Silicon semiconductor wafer for analyzing micronic biological samples
US5075077A (en) 1988-08-02 1991-12-24 Abbott Laboratories Test card for performing assays
US5188963A (en) 1989-11-17 1993-02-23 Gene Tec Corporation Device for processing biological specimens for analysis of nucleic acids
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
ATE136119T1 (en) 1988-08-18 1996-04-15 Au Membrane & Biotech Res Inst IMPROVEMENTS IN THE SENSITIVITY AND SELECTIVITY OF ION CHANNEL MEMBRANE SENSORS
US5096669A (en) 1988-09-15 1992-03-17 I-Stat Corporation Disposable sensing device for real time fluid analysis
US5849482A (en) 1988-09-28 1998-12-15 Epoch Pharmaceuticals, Inc. Crosslinking oligonucleotides
US5200051A (en) 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5219726A (en) 1989-06-02 1993-06-15 The Salk Institute For Biological Studies Physical mapping of complex genomes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3924454A1 (en) * 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg THE APPLICATION OF DNA AND DNA TECHNOLOGY FOR THE CONSTRUCTION OF NETWORKS FOR USE IN CHIP CONSTRUCTION AND CHIP PRODUCTION (DNA CHIPS)
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5750015A (en) 1990-02-28 1998-05-12 Soane Biosciences Method and device for moving molecules by the application of a plurality of electrical fields
US5126022A (en) 1990-02-28 1992-06-30 Soane Tecnologies, Inc. Method and device for moving molecules by the application of a plurality of electrical fields
DE69115690T2 (en) 1990-04-11 1996-05-30 Ludwig Inst Cancer Res METHOD AND DEVICE FOR FOLLOWING CHEMICAL REACTION PROCESS
US5166063A (en) 1990-06-29 1992-11-24 Eli Lilly And Company Immobolization of biomolecules by enhanced electrophoretic precipitation
GB2247889A (en) 1990-09-12 1992-03-18 Scient Generics Ltd DNA denaturation by an electric potential
WO1992004470A1 (en) 1990-09-12 1992-03-19 Scientific Generics Limited Electrochemical denaturation of double-stranded nucleic acid
US5527670A (en) 1990-09-12 1996-06-18 Scientific Generics Limited Electrochemical denaturation of double-stranded nucleic acid
US5227265A (en) 1990-11-30 1993-07-13 Eastman Kodak Company Migration imaging system
US5679757A (en) 1990-12-12 1997-10-21 The Regents Of The University Of California Highly organic solvent soluble, water insoluble electroluminescent polyphenylene vinylenes having pendant steroid groups and products and uses thereof
WO1992019960A1 (en) 1991-05-09 1992-11-12 Nanophore, Inc. Methods for the electrophoretic separation of nucleic acids and other linear macromolecules in gel media with restrictive pore diameters
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5849486A (en) 1993-11-01 1998-12-15 Nanogen, Inc. Methods for hybridization analysis utilizing electrically controlled hybridization
US5632957A (en) 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
US6017696A (en) 1993-11-01 2000-01-25 Nanogen, Inc. Methods for electronic stringency control for molecular biological analysis and diagnostics
US6048690A (en) 1991-11-07 2000-04-11 Nanogen, Inc. Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis
US5846708A (en) 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
US5349203A (en) * 1991-12-09 1994-09-20 Mitsubishi Denki Kabushiki Kaisha Organic electric-field switching device
JPH05236997A (en) 1992-02-28 1993-09-17 Hitachi Ltd Chip for catching polynucleotide
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9207086D0 (en) * 1992-03-31 1992-05-13 Sharp Kk Improvements relating to information technology
US5304487A (en) 1992-05-01 1994-04-19 Trustees Of The University Of Pennsylvania Fluid handling in mesoscale analytical devices
ATE256143T1 (en) * 1992-07-23 2003-12-15 Isis Pharmaceuticals Inc 2'-0-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES, METHOD FOR THEIR PRODUCTION AND USES THEREOF
US5312527A (en) 1992-10-06 1994-05-17 Concordia University Voltammetric sequence-selective sensor for target polynucleotide sequences
US5433819A (en) 1993-05-26 1995-07-18 Pressac, Inc. Method of making circuit boards
CA2170264A1 (en) 1993-09-10 1995-03-16 Michael W. Konrad Optical detection of position of oligonucleotides on large dna molecules
US5965452A (en) 1996-07-09 1999-10-12 Nanogen, Inc. Multiplexed active biologic array
US5445525A (en) 1994-05-12 1995-08-29 Intel Corporation Interconnection scheme for integrated circuit card with auxiliary contacts
ATE284894T1 (en) * 1994-10-24 2005-01-15 Genencor Int L-PYRANOSYL NUCLEOSIDES
US5718915A (en) * 1994-10-31 1998-02-17 Burstein Laboratories, Inc. Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5464517A (en) 1995-01-30 1995-11-07 Bio-Rad Laboratories Electrophoresis in low conductivity buffers
US5602262A (en) * 1995-02-03 1997-02-11 Eli Lilly And Company Process for the preparation of 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
DE59607750D1 (en) 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoester nucleic acids, process for their preparation and their use
WO1996039414A1 (en) * 1995-06-01 1996-12-12 Hybridon, Inc. Novel base protecting groups for oligonucleotide synthesis
ATE204878T1 (en) * 1995-06-23 2001-09-15 Oxford Glycosciences Uk Ltd THERAPEUTIC COMPOUNDS
WO1997005156A1 (en) 1995-07-27 1997-02-13 Carsten Behrens A new achiral linker reagent for the incorporation of multiple amino groups into oligonucleotides
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
AU7286696A (en) * 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
JP2002515738A (en) * 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド Nucleic acid analysis
GB9602028D0 (en) 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
US5660701A (en) 1996-02-29 1997-08-26 Bio-Rad Laboratories, Inc. Protein separations by capillary electrophoresis using amino acid-containing buffers
DE19651560A1 (en) * 1996-12-11 1998-06-18 Hoechst Ag New functional supramolecular nanosystems
JPH10306907A (en) * 1997-05-06 1998-11-17 Kobe Steel Ltd Fluidized bed pyrolysis method and pyrolysis fuenace as well as treating device for matter to be burnt
ATE246700T1 (en) * 1997-06-10 2003-08-15 Glaxo Group Ltd BENZIMIDAZOLE DERIVATIVES
DE19741738A1 (en) * 1997-09-22 1999-03-25 Hoechst Ag Linker nucleoside(s) containing alkenyloxy or phthalimido-alkyl groups
DE19741715A1 (en) * 1997-09-22 1999-03-25 Hoechst Ag New pentopyranosyl nucleoside compounds
AU6751800A (en) * 1999-08-13 2001-03-13 Aventis Research And Technologies Gmbh Microelectronic molecular descriptor array devices, methods, procedures, and formats for combinatorial selection of intermolecular ligand binding structures and for drug screening

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2218726A1 (en) * 2001-07-19 2010-08-18 Nanogen Recognomics GmbH Sorting and immobilization system for nucleic acids using synthetic binding systems

Also Published As

Publication number Publication date
EP1019423B1 (en) 2003-02-26
EP1017703A2 (en) 2000-07-12
WO1999015539A2 (en) 1999-04-01
KR100571299B1 (en) 2006-04-17
US7153955B2 (en) 2006-12-26
JP2001517675A (en) 2001-10-09
CA2302414A1 (en) 1999-04-01
CA2303229C (en) 2009-12-01
US20060270840A1 (en) 2006-11-30
JP2001517674A (en) 2001-10-09
US20090221793A1 (en) 2009-09-03
EP1017704A2 (en) 2000-07-12
JP4601817B2 (en) 2010-12-22
US6608186B1 (en) 2003-08-19
KR20010030656A (en) 2001-04-16
US6613894B1 (en) 2003-09-02
JP4674965B2 (en) 2011-04-20
US7777024B2 (en) 2010-08-17
DE59811296D1 (en) 2004-06-03
EP1019423A2 (en) 2000-07-19
KR20010030659A (en) 2001-04-16
WO1999015540A3 (en) 1999-06-10
EP1017704B1 (en) 2004-02-25
US20040198966A1 (en) 2004-10-07
US20050053945A1 (en) 2005-03-10
JP2001517676A (en) 2001-10-09
KR20010024202A (en) 2001-03-26
AU1024699A (en) 1999-04-12
ATE265462T1 (en) 2004-05-15
JP4674964B2 (en) 2011-04-20
WO1999015541A3 (en) 1999-06-17
CA2303784A1 (en) 1999-04-01
US7501506B2 (en) 2009-03-10
DE19741715A1 (en) 1999-03-25
WO1999015540A2 (en) 1999-04-01
AU9627198A (en) 1999-04-12
EP1017703B1 (en) 2004-04-28
AU757983B2 (en) 2003-03-13
US6506896B1 (en) 2003-01-14
WO1999015539A3 (en) 1999-06-17
BR9812381A (en) 2002-04-30
BR9812376A (en) 2000-12-12
US20030039997A1 (en) 2003-02-27
BR9812501A (en) 2000-12-12
DE59810856D1 (en) 2004-04-01
ATE260290T1 (en) 2004-03-15
AU751058B2 (en) 2002-08-08
WO1999015541A2 (en) 1999-04-01
DE59807330D1 (en) 2003-04-03
AU1024599A (en) 1999-04-12
ATE233272T1 (en) 2003-03-15

Similar Documents

Publication Publication Date Title
CA2303229A1 (en) Pentopyranosylnucleoside, its preparation and use
RU2227143C2 (en) New bicyclonucleoside analogs
CA2498731A1 (en) .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
EP0506892B1 (en) Boronated nucleosides
EP0693077B1 (en) Antiviral compounds
JP4989225B2 (en) Nucleic acid lipophilic conjugate
AU2013287630B2 (en) Chiral nucleic acid adjuvant
KR101107818B1 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
US6191266B1 (en) Sugar modified nucleosides
CA2322008A1 (en) 2'-fluoronucleosides
JP2006516949A5 (en)
EP0321548A4 (en) Novel amphiphilic nucleic acid conjugates
JP2004513070A5 (en)
CZ274596A3 (en) Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
KR960705834A (en) PNA-DNA-PNA Hybrid Macromolecules
US10947543B2 (en) Interferon production using short RNA duplexes
US6548486B1 (en) Fatty acid esters of nucleoside analogs
CA2210492A1 (en) Neuraminic acid derivatives, their preparation and their medical use
CA2393042A1 (en) Antithrombotic compound
CA2340931A1 (en) 3'-deoxypentopyranosylnucleic acid, its preparation and use
AU732120B2 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
CA2212877A1 (en) Specific lipid conjugates of nucleoside diphosphates and their use as drugs
WO2010090969A4 (en) Tetrahydropyran nucleic acid analogs
US6743902B1 (en) Sugar modified nucleosides
CA1295269C (en) Polynucleotide analogs, methods for inhibiting nucleic acid polymerases and methods for inducing synthesis of interferon

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160921